Name: Gilead Sciences Inc. (NASDAQ:GILD) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Gilead Sciences Inc., income statement, revenues

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
HIV	18,175)	17,194)	16,315)	16,938)	16,438)
Cell Therapy	1,869)	1,459)	871)	607)	456)
Trodelvy	1,063)	680)	380)	49)	—)
Oncology	2,932)	2,139)	1,251)	656)	456)
Chronic hepatitis C virus (HCV)	1,767)	1,810)	1,881)	2,064)	2,936)
Chronic hepatitis B virus (HBV)/Chronic hepatitis delta virus (HDV)	1,017)	988)	969)	860)	742)
Liver Disease	2,784)	2,798)	2,850)	2,924)	3,678)
Veklury	2,184)	3,905)	5,565)	2,811)	—)
Other	859)	946)	1,027)	1,026)	1,547)
Product sales	26,934)	26,982)	27,008)	24,355)	22,119)

Download chart

Item	Description	The company
Product sales	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Gilead Sciences Inc. product sales decreased from 2021 to 2022 and from 2022 to 2023.